Trial Summary
What is the purpose of this trial?
The investigators propose to use Belinostat in combination with AZT as consolidation therapy for the treatment of ATLL.
Eligibility Criteria
Adults with Adult T-Cell Leukemia-Lymphoma (ATLL) who have had some treatment and a partial response can join. They must be over 18, have certain blood counts and liver/kidney function, not be pregnant or breastfeeding, agree to use birth control, and cannot have other serious health issues or another active cancer.Inclusion Criteria
I have been diagnosed with aggressive adult T-cell leukemia/lymphoma.
Creatinine clearance (CrCl) ≥ 40 mL/min
HIV+ patients eligible
See 13 more
Exclusion Criteria
I do not have any other active cancers.
Conditions likely to interfere with study requirements/treatment
My liver issues are not caused by lymphoma.
See 8 more
Treatment Details
Interventions
- Belinostat (Histone Deacetylase Inhibitor)
- Zidovudine (Nucleoside Reverse Transcriptase Inhibitor)
Trial OverviewThe trial is testing Belinostat combined with Zidovudine as a follow-up therapy for ATLL. Participants will already have received some treatment for ATLL and shown improvement without new disease progression.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Belinostat + ZidovudineExperimental Treatment4 Interventions
Belinostat + Zidovudine (AZT) in combination as consolidation therapy, followed by standard zidovudine (AZT)-based maintenance therapy with optional Interferon-Alfa-2b (IFNalfa-2b) or Pegylated Interferon-Alfa-2b (PEG-IFN-alfa-2b)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of MiamiMiami, FL
Loading ...
Who Is Running the Clinical Trial?
University of MiamiLead Sponsor